我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
1
33.3%
已完成
招募中
暂无批准数据
- Aldeyra Therapeutics resubmitted its NDA for reproxalap, targeting dry eye disease symptoms with both acute and chronic activity demonstrated in trials. - Aviceda Therapeutics completed enrollment for its Phase 2b SIGLEC study, evaluating AVD-104 for geographic atrophy secondary to age-related macular degeneration. - Ocular Therapeutix accelerates the SOL-1 Phase 3 trial of Axpaxli for wet AMD, expecting topline data in Q4 2025.
